Subcutaneous Cetuximab Is Not Less Adverse than IV Administerion in Relapsing Primary Progressive Multiple Sclerosis Patients.

Published Date: 15 Oct 2023

Comparable to intravenous therapy, the subcutaneous 920-mg dose produced almost total suppression of radiological and clinical disease activity as assessed through week 24.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot